Non-Hodgkin Lymphoma — Trials

Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,168
Recruiting: 1,127
Ph III recruiting: 115
Growth YoY: +5.7%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%
Trials / 1,000 deaths: 108.5 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,290)

clinicaltrialsPublishedShowing 451–500 of 1,212 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07217184	Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM	active not recruiting	Phase 1 / Phase 2	30	GlaxoSmithKlineINDUSTRY	11	Jun 25, 2026	clinicaltrials
NCT07453095	Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy	recruiting	Phase 2	41	Fondazione Italiana Linfomi - ETSOTHER	1	Jun 25, 2026	clinicaltrials